23andMe's stock has mostly been in free fall in recent years as the company struggled to generate recurring revenue and stand up viable research and therapeutics businesses. As of Monday morning, the company has a market capitalization of around $25 million.
Last March, 23andMe's independent directors formed a special committee to evaluate the company's potential paths forward. Wojcicki submitted multiple proposals to take the company private, but all were rejected. The special committee "unanimously determined to reject" Wojcicki's most recent proposal earlier this month.